Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

SNX-111 Chronic Pain Study Results To Be Presented WASHINGTON—Nov. 18, 1996 -- Dr. William Brose, director of the Pain Management Center for Stanford University, reported detailed study results from a chronic pain study with SNX-111 at the American Pain Society on Saturday, Nov. 16. The paper, entitled, "Analgesia Produced by SNX-111 in Patients With Morphine-Resistant Pain," represented the work from multiple centers and described both the safety and efficacy of SNX-111 in this study to treat patients with very severe pain. SNX-111 is the lead pain therapeutic under development by Neurex Corp. (NASDAQ/NM:NXCO). The majority of patients that were considered evaluable in this study, showed a measurable reduction in pain scores, as judged by both patient and physician. In addition, most patients also had significant reduction in other medications that had been used prior to the study in an attempt to treat, albeit unsuccessfully, their pain symptoms. Over two-thirds of the 24 patients had a 50% or greater reduction in medication, with some patients totally eliminating morphine/narcotic use. "Although the study was primarily designed to evaluate the feasibility and efficacy of SNX-111 treatment in these severely ill patients, it is clear that as a patient group, a majority of these individuals seem to have benefited from improvements in their pain symptoms with SNX-111 treatment," commented Dr. Brose. "To see such a reduction in both their pain scores and use of their pain medications in this patient population is quite remarkable. For patients with prolonged and unremitting pain, SNX-111 represents potential hope and light at the end of a very long and dark tunnel." The study evaluated the safety and efficacy of intraspinally administered SNX-111 to patients who had previously failed morphine therapy. Study guidelines required that patients had to have failed all other pain treatment (including intraspinal morphine and other narcotics) prior to study enrollment. Patients were entered into the study who had a variety of severe and resistant pain including those who were suffering from cancer, AIDS, neuropathies, spinal cord injuries and phantom limb pain. Neurex Corp. is developing products for acute care, principally in the areas of cardiorenal and neurological diseases. The company focuses on the discovery, development and commercialization of products for acute care therapies, including emergency room, intensive care unit and pain clinic settings. Neurex' products under development, CORLOPAM and SNX-111, are currently in advanced stage human trials, each with the potential to treat multiple indications. E-mail this page to a friend or colleague! To print, use this version